Hypoglycemics, Insulin-Response Enhancer-Thiazolidinediones

The phrase "Hypoglycemics, Insulin-Response Enhancer-Thiazolidinediones" reflects a specialized formulary classification for thiazolidinediones, an established class of oral antidiabetic agents that function as insulin sensitizers

The phrase "Hypoglycemics, Insulin-Response Enhancer-Thiazolidinediones" reflects a specialized formulary classification for thiazolidinediones, an established class of oral antidiabetic agents that function as insulin sensitizers

The phrase "Hypoglycemics, Insulin-Response Enhancer-Thiazolidinediones" reflects a specialized formulary classification for thiazolidinediones, an established class of oral antidiabetic agents that function as insulin sensitizers

These medications exert their therapeutic effect by acting as selective agonists for peroxisome proliferator-activated receptor-gamma nuclear receptors in target tissues, including adipose tissue, skeletal muscle, and the liver Activation of these receptors modulates gene transcription involved in glucose and lipid metabolism, ultimately enhancing target-tissue sensitivity to insulin and improving peripheral glucose utilization without stimulating additional pancreatic insulin secretion

Activation of these receptors modulates gene transcription involved in glucose and lipid metabolism, ultimately enhancing target-tissue sensitivity to insulin and improving peripheral glucose utilization without stimulating additional pancreatic insulin secretion

Consequently, this drug class is primarily indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus